Form 4: Bausch + Lomb CFO Receives Significant RSU Grant

Bausch + Lomb Corporation's EVP and CFO, Sam Eldessouky, was granted 81,775 restricted share units as part of the company's incentive plan.

Summary

• Sam Eldessouky, Executive Vice President and Chief Financial Officer of Bausch + Lomb Corporation (BLCO), was granted 81,775 restricted share units (RSUs).
• The RSUs were issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• These RSUs are scheduled to vest one-third on each of the first three anniversaries of the grant date, which was February 25, 2026.
• Vesting is contingent upon the reporting person's continued service and adherence to the terms of the Plan and the applicable award agreement.
• Following this transaction, Eldessouky's beneficial ownership stands at 473,169 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term company performance and shareholder interests.

Positives

• The grant of 81,775 restricted share units to a key executive like the EVP and CFO aligns management's long-term interests with those of shareholders.
• The award is part of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, indicating a structured and approved approach to executive compensation and retention.

Risks

• The vesting of the restricted share units is subject to the reporting person's continued service, meaning the shares are not immediately owned and could be forfeited if employment ceases before the vesting dates.

Future Outlook

The vesting schedule for the granted restricted share units extends over three years, with one-third vesting annually, indicating a long-term retention strategy for the EVP and CFO and a focus on sustained performance.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants like RSUs is a standard practice across the pharmaceutical and medical device industries. This aligns executive incentives with long-term shareholder value creation, a common strategy for retaining key talent in competitive sectors.

Comparison to Industry Standards

• The grant of restricted share units (RSUs) to a senior executive like the CFO is a common compensation practice in the healthcare and pharmaceutical industry, similar to companies such as Johnson & Johnson, Pfizer, and Medtronic, which frequently use equity awards to incentivize long-term performance and retention.
• The vesting schedule of one-third annually over three years is a typical structure for RSU grants, comparable to industry benchmarks aimed at fostering sustained executive commitment rather than short-term gains.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive plans.

Next Steps

• Vesting of one-third of the granted RSUs on February 25, 2027, subject to continued service.
• Vesting of one-third of the granted RSUs on February 25, 2028, subject to continued service.
• Vesting of the final one-third of the granted RSUs on February 25, 2029, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a key executive, which is a standard component of executive compensation designed to align management incentives with long-term shareholder value. It does not provide new information that would fundamentally alter the investment thesis for Bausch + Lomb, thus a 'hold' recommendation is appropriate as it neither signals a significant positive catalyst nor a negative concern that would warrant a change in existing positions.

Keywords

Bausch + Lomb, BLCO, Sam Eldessouky, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Form 4, Omnibus Incentive Plan